Clinical Trials Logo

Clinical Trial Summary

This is a study on the clinical application of chimeric antigen receptor modified γδ T cells (CAR - γδ T cells) in relapsed and refractory CD7 Positive T cell-derived malignant tumors.The main purpose of this study was to evaluate the efficacy of car - γ δ T cell infusion in patients with relapsed and refractory CD7 Positive T cell-derived malignancies.


Clinical Trial Description

γδT cells are known as "a great candidate for car-t cells". Although they only account for 2% - 5% of all T cells in our body, they are a natural killer. CD7 is recognized as a sensitive marker of T-ALL, and its expression level on T-ALL cells is opposite to CD3: compared with normal T cells, the expression level of CD7 on T-ALL cells is significantly increased (P < 0.001), while the expression level of CD3 on T-ALL cells is significantly decreased (P < 0.001). At the same time, CD7 expression is absent in about 10% of normal T cells, and these CD7 negative T cells have the ability of normal T cells to express cytokines. Therefore, CD7 has become a potential target for the treatment of T-ALL because of its specificity and safety. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04702841
Study type Interventional
Source PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Contact Xingbing Wang
Phone 13856007984
Email wangxingbing@ustc.edu.cn
Status Recruiting
Phase Early Phase 1
Start date June 3, 2020
Completion date December 2022

See also
  Status Clinical Trial Phase
Completed NCT02041871 - Interest of PReOPerative Immunonutrition in Liver Surgery for Cancer N/A
Completed NCT03110783 - Bioseal Dural Sealing Study BIOS-14-001 Phase 3
Recruiting NCT05516914 - A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors Phase 1/Phase 2
Completed NCT02534506 - Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors Phase 1
Recruiting NCT05714748 - Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors Phase 1
Recruiting NCT05987098 - BBPA PET/CT in Patients With Malignant Tumors N/A
Not yet recruiting NCT01092247 - The Effect of Ketogenic Diet on Malignant Tumors- Recurrence and Progress N/A
Recruiting NCT03160599 - Restricted Calorie Ketogenic Diet as a Treatment in Malignant Tumors N/A
Completed NCT00165100 - Dynamic Area Telethermometry (DAT) as an Imaging Modality in Patients With Cancer N/A
Suspended NCT05615974 - A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors Phase 1/Phase 2
Completed NCT03542773 - Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET Phase 1
Completed NCT05293990 - Usefulness of Gadovist-enhanced FLAIR Imaging N/A
Completed NCT01509612 - Additive Homeopathy in Cancer Patients Phase 3
Completed NCT01678690 - An Exploratory Study of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors Phase 0
Suspended NCT06270394 - FAP PET/CT or PET/MR Production in the Diagnosis, Staging, and Efficacy Assessment of Malignant Tumors Application N/A
Completed NCT00412503 - Temozolomide in Association With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents Phase 1